A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06)
Latest Information Update: 16 Oct 2024
At a glance
- Drugs Acasunlimab (Primary) ; Pembrolizumab (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms ABBIL1TY NSCLC-06
- Sponsors Genmab
- 16 Oct 2024 New trial record